Pancreatic β-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 14, Issue 11, 2012, Pages 1010-1019

  Muhammed, S J ^a   Lundquist, I ^a,b   Salehi, A ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

CAMP PKA system; INOS expression; Insulin secretion; Phosphodiesterase; Type 2 diabetic islets

Indexed keywords

AMINOGUANIDINE; BUCLADESINE; CILOSTAZOL; CYCLIC AMP; GLUCAGON; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; MILRINONE; NITRITE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IIIA; PHOSPHODIESTERASE IIIB; PHOSPHODIESTERASE INHIBITOR; SOMATOSTATIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CONFOCAL MICROSCOPY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; INSULIN RELEASE; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN SECRETION; RADIOIMMUNOASSAY; REACTION TIME; SOMATOSTATIN CELL; WESTERN BLOTTING;

EID: 84867142480     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01632.x     Document Type: Article

References (39)

1. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V, Kevorkian JP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 2008; 34:(Suppl 2) S43-48.
2. Hellman B, Salehi A, Gylfe E, Dansk H, Grapengiesser E. Glucose generates coincident insulin and somatostatin pulses and antisynchronous glucagon pulses from human pancreatic islets. Endocrinology 2009; 150: 5334-5340.
3. Marshak S, Leibowitz G, Bertuzzi F et al. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 1999; 48: 1230-1236.
4. Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and [beta]-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008; 9: 193-205.
5. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev 2008; 29: 351-366.
6. Chang-Chen K, Mullur R, Bernal-Mizrachi E β-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008; 9: 329-343.
7. Akesson B, Henningsson R, Salehi A, Lundquist I. Islet constitutive nitric oxide synthase and glucose regulation of insulin release in mice. JEndocrinol 1999; 163: 39-48.
8. Henningsson R, Salehi A, Lundquist I. Role of nitric oxide synthase isoforms in glucose-stimulated insulin release. Am J Physiol Cell Physiol 2002; 283: C296-304.
9. Mosén H, Östenson C-G, Lundquist I et al. Impaired glucose-stimulated insulin secretion in the GK rat is associated with abnormalities in islet nitric oxide production. Regul Pept 2008; 151: 139-146.
10. Salehi A, Meidute Abaraviciene S, Jimenez-Feltstrom J, Östenson C-G, Efendic S, Lundquist I. Excessive islet NO generation in type 2 diabetic GK rats coincides with abnormal hormone secretion and is counteracted by GLP-1. PLoS ONE 2008; 3: e2165.
11. Jimenez-Feltstrom J, Salehi A, Meidute Abaraviciene S, Henningsson R, Lundquist I. Abnormally decreased NO and augmented CO production in islets of the leptin-deficient ob/ob mouse might contribute to explain hyperinsulinemia and islet survival in leptin-resistant type 2 obese diabetes. Regul Pept 2011; 170: 43-51.
12. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593-615.
13. Christopherson KS, Bredt DS. Nitric oxide in excitable tissues: physiological roles and disease. J Clin Invest 1997; 100: 2424-2429.
14. Corbett JA, Sweetland MA, Wang JL, Lancaster JR, McDaniel ML. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci 1993; 90: 1731-1735.
15. Rabinovitch A, Suarez-Pinzon WL, Sorensen O, Bleackley RC. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: identification of iNOS- expressing cells and relationships to cytokines expressed in the islets. Endocrinology 1996; 137: 2093-2099.
16. Salehi A, Ekelund M, Henningsson R, Lundquist I. Total parenteral nutrition modulates hormone release by stimulating expression and activity of inducible nitric oxide synthase in rat pancreatic islets. Endocrine 2001; 16: 97-104.
17. Salehi A, Ekelund M, Lundquist I. Total parenteral nutrition-stimulated activity of inducible nitric oxide synthase in rat pancreatic islets is suppressed by glucagon-like peptide-1. Horm Metab Res 2003; 35: 48-54.
18. Jimenez-Feltstrom J, Lundquist I, Salehi A. Glucose stimulates the expression and activities of nitric oxide synthases in incubated rat islets: an effect counteracted by GLP-1 through the cyclic AMP/PKA pathway. Cell Tissue Res 2005; 319: 221-230.
19. Qader SS, Jimenez-Feltström J, Ekelund M, Lundquist I, Salehi A. Expression of islet inducible nitric oxide synthase and inhibition of glucose-stimulated insulin release after long-term lipid infusion in the rat is counteracted by PACAP27. Am J Physiol Endocrinol Metab 2007; 292: E1447-1455.
20. Abaraviciene S, Lundquist I, Salehi A. Rosiglitazone counteracts palmitate-induced β-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities. Cell Mol Life Sci 2008; 65: 2256-2265.
21. Kumar R, Balhuizen A, Amisten S, Lundquist I, Salehi A. Insulinotropic and antidiabetic effects of 17β-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 2011; 152: 2568-2579.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
23. Pyne N, Furman B. Cyclic nucleotide phosphodiesterases in pancreatic islets. Diabetologia 2003; 46: 1179-1189.
24. Delmastro MM, Piganelli JD. Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol 2011; 2011: 1-15.
25. Panagiotidis G, Akesson B, Rydell EL, Lundquist I. Influence of nitric oxide synthase inhibition, nitric oxide and hydroperoxide on insulin release induced by various secretagogues. Br J Pharmacol 1995; 114: 289-296.
26. Salehi A, Carlberg M, Henningson R, Lundquist I. Islet constitutive nitric oxide synthase: biochemical determination and regulatory function. Am J Physiol Cell Physiol 1996; 270: C1634-1641.
27. Tsuura Y, Ishida H, Shinomura T, Nishimura M, Seino Y. Endogenous nitric oxide inhibits glucose-induced insulin secretion by suppression of phosphofructokinase activity in pancreatic islets. Biochem Biophys Res Commun 1998; 252: 34-38.
28. Lajoix A-D, Reggio H, Chardès T et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic β-cells controls insulin secretion. Diabetes 2001; 50: 1311-1323.
29. Mosén H, Salehi A, Alm P et al. Defective glucose-stimulated insulin release in the diabetic Goto-Kakizaki (GK) rat coincides with reduced activity of the islet carbon monoxide signaling pathway. Endocrinology 2005; 146: 1553-1558.
30. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol 2001; 3: 193-197.
31. Hess DT, Matsumoto A, Kim S-O, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 2005; 6: 150-166.
32. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009; 15: 391-404.
33. Takamura T, Kato I, Kimura N et al. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic β cells develop insulin-dependent diabetes without insulitis. J Biol Chem 1998; 273: 2493-2496.
34. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004; 53:(Suppl 3) S16-S21.
35. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
36. Åkesson B, Lundquist I. Nitric oxide and hydroperoxide affect islet hormone release and Ca(2+) efflux. Endocrine 1999; 11: 99-107.
37. Kang J-H, Chang S-Y, Jang H-J et al. Exendin-4 inhibits interleukin-1β-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F β-cells. J Endocrinol 2009; 202: 65-75.
38. Li F, Mahato RI. iNOS gene silencing prevents inflammatory cytokine-induced β-cell apoptosis. Mol Pharm 2008; 5: 407-417.
39. Lee JH, Park SY, Shin HK, Kim CD, Lee WS, Hong KW. Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury. CNS Neurosci Ther 2008; 14: 143-152.